Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

¿µºëÒ©Òµ1ÀàMASHÁ¢ÒìÒ©ÔÚÖйú»ñÅúÁÙ´²

2024-10-20
|
»á¼ûÁ¿£º

΢ÐÅͼƬ_20241016163851.jpg

Ò½ÏßÒ©ÎÅ

1. 10ÔÂ18ÈÕ£¬£¬£¬£¬¾ÝCDE¹ÙÍøÐÂÎÅ£¬£¬£¬£¬³É¶¼¿µºëÒ©Òµ¼¯ÍŹɷÝÓÐÏÞ¹«Ë¾ÁªºÏÉêÇëÒ©Æ·¡°KH629Ƭ¡±£¬£¬£¬£¬»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬Ë³Ó¦Ö¢£º±¾Æ·ÓÃÓÚÖÎÁƳÉÈ˷Ǿƾ«ÐÔÖ¬·¾ÐÔ¸ÎÑס£¡£ ¡£KH629ƬÊÇÒ»¿î¼××´ÏÙ¼¤ËئÂÊÜÌåÑ¡ÔñÐÔ¼¤¶¯¼Á¡£¡£ ¡£

2. 10ÔÂ19ÈÕ£¬£¬£¬£¬°²Ë¹Ì©À´£¨Astellas Pharma£©Ðû²¼ÃÀ¹úFDAÒÑÅú×¼Æä°ÐÏòClaudin18.2£¨CLDN18.2£©¿¹ÌåVyloy£¨zolbetuximab£©Ó뺬·úà×ऺͲ¬ÀàµÄ»¯ÁƼƻ®ÁªºÏ£¬£¬£¬£¬ÓÃÓÚ¾Ö²¿ÍíÆÚ²»¿ÉÇгý»ò×ªÒÆÐÔ¡¢HER2ÒõÐÔµÄθ°©»òθʳ¹ÜÁ¬Ïµ²¿£¨GEJ£©ÏÙ°©³ÉÈË»¼ÕßµÄÒ»ÏßÖÎÁÆ£¬£¬£¬£¬ÕâЩ»¼ÕßµÄÖ×ÁöÐèͨ¹ýFDAÅú×¼µÄ¼ì²âÈ·¶¨ÎªCLDN18.2ÑôÐÔ¡£¡£ ¡£

3. 10ÔÂ18ÈÕ£¬£¬£¬£¬°¬²®Î¬£¨AbbVie£©Ðû²¼£¬£¬£¬£¬ÃÀ¹úFDAÒÑÅú×¼Vyalev£¨foscarbidopaºÍfoslevodopa£©ÉÏÊУ¬£¬£¬£¬ÓÃÓÚÖÎÁÆÍíÆÚÅÁ½ðÉ­²¡£¡£ ¡£¨PD£©³ÉÈË»¼ÕßµÄÔ˶¯ÄÜÁ¦²¨¶¯¡£¡£ ¡£ÐÂΟåÖ¸³ö£¬£¬£¬£¬ÕâÊÇFDAÅú×¼µÄÊ׿î»ùÓÚ×óÐý¶à°ÍµÄƤÏÂ24СʱһÁ¬Êä×¢ÁÆ·¨¡£¡£ ¡£¡£¡£ ¡£

4. 10ÔÂ18ÈÕ£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬°¢Ë¹Àû¿µ(AZN.US)Á½¿îÐÂÒ©µÄÉÏÊÐÉêÇë»ñµÃÊÜÀí£¬£¬£¬£¬Ïêϸ˳Ӧ֢ÉÐδÅû¶¡£¡£ ¡£¶È·¥ÀûÓȵ¥¿¹(durvalumab)×¢ÉäҺΪһ¿îPD-L1ÒÖÖÆ¼Á£¬£¬£¬£¬tremelimumabΪһ¿î¿¹CTLA-4µ¥¿¹¡£¡£ ¡£´ÓÊÜÀíºÅ¿ÉÒÔÍÆ²â£¬£¬£¬£¬±¾´ÎÉ걨ÉÏÊеĿÉÄÜΪ¶þÕß×é³ÉµÄÁªºÏÁÆ·¨£¬£¬£¬£¬¸ÃÁªºÏÁÆ·¨´ËǰÔÚÈ«Çò¹æÄ£ÄÚ»ñî¿Ïµ»ú¹¹Åú×¼ÓÃÓÚÖÎÁÆ·ÇСϸ°û·Î°©Ò»ÏßÖÎÁƺ͸Îϸ°û°©Ò»ÏßÖÎÁÆ¡£¡£ ¡£

ͶÈÚÒ©ÊÂ

1. ¿ËÈÕ£¬£¬£¬£¬êÍÖÂÒ½Ò©£¨Viatris£©»ñµÃ Lexicon Pharmaceutical ¶À¼ÒÔÊÐí£¬£¬£¬£¬¿ÉÔÚÃÀ¹úºÍÅ·ÖÞÒÔÍâµÄËùÓÐ˳Ӧ֢ÖÐÉÌÒµ»¯ SGLT-1/2 ˫ЧÒÖÖÆ¼Á Sotagliflozin£¬£¬£¬£¬Lexicon ±£´æÁ˸ÃÒ©ÔÚÃÀ¹úºÍÅ·ÖÞËùÓÐ˳Ӧ֢µÄ¶À¼ÒÉÌÒµ»¯È¨Á¦¡£¡£ ¡£Îª´Ë£¬£¬£¬£¬Lexicon ¹«Ë¾½«»ñµÃ 2500 ÍòÃÀÔªµÄÔ¤¸¶¿î¼°Ç±ÔÚî¿ÏµºÍÉÌÒµÀï³Ì±®¸¶¿î¡£¡£ ¡£

¿Æ¼¼Ò©ÑÐ

1. ¿ËÈÕ£¬£¬£¬£¬Ò»Æª½ÒÏþÔÚ¹ú¼ÊÔÓÖ¾NatureÉÏÌâΪ¡°Glucose-sensitive insulin with attenuation of hypoglycaemia¡±µÄÑо¿±¨¸æÖУ¬£¬£¬£¬À´×Ôµ¤ÂóŵºÍŵµÂÖÆÒ©¹«Ë¾µÈ»ú¹¹µÄ¿ÆÑ§¼ÒÃÇͨ¹ýÑо¿·¢Ã÷£¬£¬£¬£¬Ò»ÖÖÄܱÜÃâ»úÌåѪÌÇͻȻϽµµÄ¸ÄÁ¼°æ±¾ÒȵºËØÒѾ­ÔÚʵÑéÊÒʵÑéºÍ¶¯ÎïÄ£×ÓÖлñµÃ֤ʵ£¬£¬£¬£¬Õâ»òÐí¾ÍÄÜΪÌÇÄò²¡»¼ÕßÌṩһÖÖ¸üÎÞаµÄÔö²¹ÒȵºËصÄÊֶΣ¬£¬£¬£¬²¢ÄÜïÔÌ­Æä»úÌåѪÌǵÄͻȻϽµ¡£¡£ ¡£

[1]Hoeg-Jensen, T., Kruse, T., Brand, C.L. et al. Glucose-sensitive insulin with attenuation of hypoglycaemia. Nature (2024). doi£º10.1038/s41586-024-08042-3

Ïà¹ØÐÂÎÅ
¿µºëÒ©Òµ½ºÖÊĸϸ°ûÁöÁ¢ÒìÒ©»ñFDA¹Â¶ùÒ©È϶¨Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-02-16
¿µºëÒ©ÒµÐû²¼Í¨¸æÐû²¼£¬£¬£¬£¬×Ó¹«Ë¾ËÄ´¨ºëºÏÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾KH617ÓÚ2ÔÂ14ÈÕ»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö(FDA)Õë¶Ô½ºÖÊĸϸ°ûÁöµÄ¹Â¶ùÒ©×ʸñÈ϶¨¡£¡£ ¡£KH617ÊǺëºÏÉúÎï×ÔÖ÷Ñз¢µÄÄâÓÃÓÚÖÎÁÆÍíÆÚʵÌåÁöºÍ¸´·¢½ºÖÊĸϸ°ûÁö»¼ÕߵľßÓÐ×ÔÖ÷֪ʶ²úȨµÄÁ¢ÒìÒ©¡£¡£ ¡£
ÓÃÓÚÖÎÁƷǾƾ«ÐÔÖ¬·¾ÐÔ¸ÎÑ×µÄPPAR¦Á/¦Ä Ë«ÖØ¼¤¶¯¼ÁµÄÉè¼ÆºÏ³ÉºÍÉúÎïѧÆÀ¼Û£¬£¬£¬£¬PKÑо¿¡¢hERGÑо¿ºÍAmesÊÔÑéͨ¹ýÃÀ¸ß÷¾ÙÐÐ
2023-07-05
Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPAR¦Á/¦Ä are regarded as potential therapeutic targets for NASH. Herein, researchers report a series of novel triazolone derivatives as PPAR¦Á/¦Ä dual agonists. The pharmacokinetic studies were conducted by Medicilon. The hERG channel inhibition studies were conducted by Medicilon. The Ames tests were conducted by Medicilon.
º£´´Ò©ÒµHP515Ƭ»ñÅúFDA£¬£¬£¬£¬ÓÃÓÚÖÎÁÆ´úлÐÔÖ¬·¾ÐÔ¸ÎÑ×£¨MASH£©
2024-09-14
9ÔÂ13ÈÕ£¬£¬£¬£¬º£´´Ò©ÒµÐû²¼Í¨¸æ³Æ£¬£¬£¬£¬¿ËÈÕº£´´Ò©Òµ¹É·ÝÓÐÏÞ¹«Ë¾ÊÕµ½ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾ÖµÄÁÙ´²Ñо¿¼ÌÐø¾ÙÐÐ֪ͨÊ飬£¬£¬£¬¹«Ë¾×ÔÖ÷Ñз¢µÄHP515ƬÓÃÓÚÖÎÁÆ´úлÐÔÖ¬·¾ÐÔ¸ÎÑ×£¨MASH£©µÄÁÙ´²ÊÔÑéÉêÇëÕýʽ»ñµÃFDAÅú×¼¡£¡£ ¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿